First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Published:2012-11 Issue:11 Volume:13 Page:1161-1170
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lee Siow Ming,Khan Iftekhar,Upadhyay Sunil,Lewanski Conrad,Falk Stephen,Skailes Geraldine,Marshall Ernie,Woll Penella J,Hatton Matthew,Lal Rohit,Jones Richard,Toy Elizabeth,Chao David,Middleton Gary,Bulley Sue,Ngai Yenting,Rudd Robin,Hackshaw Allan,Boshoff Chris

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer;Davidoff;J Clin Oncol,2010

3. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer;Reguart;Cancer Manag Res,2010

4. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol,2010

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisão Sistemática de Estudos Observacionais sobre o uso de Erlotinibe e Gefitinibe no Tratamento do Câncer de Pulmão de Células Não Pequenas;Revista Brasileira de Cancerologia;2024-08-30

2. Thoracic radiation in combination with erlotinib—results from a phase 2 randomized trial;Frontiers in Oncology;2024-08-01

3. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

4. Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors;Cancers;2024-05-23

5. Mismatch Between Brain MRIs and 18F-DOPA PET/CT;Clinical Nuclear Medicine;2024-02-09